Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo.

Cancer medicine - 1 Sept 2015

Wood Joanna P, Smith Andrew J O, Bowman Karen J, Thomas Anne L, Jones George D D

Abstract excerpt

The use of irinotecan to treat metastatic colorectal cancer (CRC) is limited by unpredictable response and variable toxicity; however, no reliable clinical biomarkers are available. Here, we report a study to ascertain whether irinotecan-induced DNA damage measures are suitable/superior biomarkers of irinotecan effect. CRC-cell lines (HCT-116 and HT-29) were treated in vitro with irinotecan and peripheral blood...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to Comet Assay

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Repetitive Sequences, Nucleic Acid

Share to Topoisomerase I Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 26108357
DOI: 10.1002/cam4.477
PMCID: PMC4567016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo.PMID 26108357Read ↗

Assessment of chemotherapy‐induced DNA damage in peripheral blood leukocytes of cancer patients using the alkaline comet assaySemantic proximity Read ↗

DNA damage and repair measured by comet assay in cancer patientsSemantic proximity Read ↗

Multiple end‐point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: Implications for predictive testingSemantic proximity Read ↗

Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapySemantic proximity Read ↗

Relationship between clonogenic radiosensitivity, radiation-induced apoptosis and DNA damage/repair in human colon cancer cellsSemantic proximity Read ↗

Differences in nucleotide excision repair capacity between newly diagnosed colorectal cancer patients and healthy controls.Semantic proximity Read ↗

BRAF V600E-induced distinct DNA damage response defines the therapeutic potential of p53 activation for TP53 wild-type colorectal cancer.Semantic proximity Read ↗

Long-lasting reduction in clonogenic potential of colorectal cancer cells by sequential treatments with 5-azanucleosides and topoisomerase inhibitors.Semantic proximity Read ↗

Genetic toxicity assessment: employing the best science for human safety evaluation part III: the comet assay as an alternative to in vitro clastogenicity tests for early drug candidate selection.Semantic proximity Read ↗

Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assaySemantic proximity Read ↗

In Vivo Topoisomerase I Inhibition Attenuates the Expression of Hypoxia-Inducible Factor 1α Target Genes and Decreases Tumor AngiogenesisSemantic proximity Read ↗

Measurements using the alkaline comet assay predict bladder cancer cell radiosensitivitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.